sar302503
sar302503: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: BRISTOL MYERS SQUIBB CO (BMY)
Development Pipeline (1)
| Company | Phase |
|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | Phase 2 |
Clinical Trials (1)
A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated With Ruxolitinib and With a Current Diagnosis of Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Frequently asked questions
Who is developing sar302503?
sar302503 is being developed by BRISTOL MYERS SQUIBB CO.
How many clinical trials involve sar302503?
BioSniper tracks 1 clinical trial involving sar302503.
Analyze BRISTOL MYERS SQUIBB CO & sar302503 with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company